

QUARTERLY ACTIVITIES & CASHFLOW REPORT


Highlights

- Record receipts from customers of \$5M; up 57% or \$1.8M from the Sep quarter of \$3.2M and up \$3M or 142% from the pcp of \$2.1M
- Record cash receipts from customers over the last 12 months (LTM) to 31 Dec 2024 of \$13.1M up 29% or \$2.9M from LTM at 30 Sep 2024
- Positive cashflows from operating activities of \$1.1M, and net positive cashflows from operating activities of \$2.5M for the 12 months to 31 Dec 2024
- Major clinical trial announced in Nov 2024 worth \$13.8M over 24 months, with total major clinical trial contract wins totalling \$20.1M since Aug 2023
- Major clinical trial announced in Aug 2023 progressing to schedule with completion planned for the second half of FY25
- Additional deferred acquisition payments of \$3.2M made to TrialsWest vendors in the quarter due to TrialsWest trading significantly ahead of initial expectations
- New TrialsWest site being planned south of Perth
- Cash at bank of \$3.5M at the end of the quarter and net cash of \$0.5M (net of \$3.0M bank debt)

Resonance Health Ltd (ASX: RHT) (**Resonance Health** or **Company**) is pleased to release its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter ended 31 December 2024.

Major Milestones

The Company continues to rapidly and profitably scale up its operations with the execution of its strategy to drive growth in its 3-business focus areas (**Group**); Software-as-a-Medical Device (**SaMD**), Clinical Trial Management (**CRO Services**), and Clinical Trial Site Services (**TrialsWest**) – achieving record receipts from customers for the Group of \$5M for the quarter.



For personal use only

CRO Services won another trial worth \$13.8M over 24-months, taking total contract wins to over \$20M since August 2023 (see ASX releases dated 19 November 2024 and 18 August 2023). The CRO Services business unit receipted \$2.4M during the quarter with respect to the management of these clinical trials for an international major pharma customer. Across both clinical trials currently being managed by CRO Services there remains ~\$13.3M to be invoiced over the projected remaining trial timeframe of 24 months.

The TrialsWest business continued to trade strongly, and because of TrialsWest's strong FY2024 trading performance, in accordance with the terms of the TrialsWest acquisition, the Company paid deferred consideration of \$3.2M to the TrialsWest vendors during the quarter (see ASX release dated 2 April 2024).

The second TrialsWest trial site which opened north of Perth in August 2024 (see ASX release dated 8 August 2024) contributed to the Group in line with expectations during the quarter with a third site planned to open south of Perth in the coming months. The capacity of the 3 trial sites allows the Company to better fulfill the site requirements of the new major-pharma clinical trial referenced above and announced on 19 November 2024. It also provides increased capacity to serve TrialsWest's various existing pharma customers.

In the SaMD business, the Company agreed during the quarter to provide a new central-read analysis service for Magnetic Resonance Elastography (**MRE**) which is an MRI based method of measuring liver stiffness. This service will initially only be provided to the major clinical trial referenced above (announced on 19 November 2024) that is being managed by CRO Services. The provision of central-read services for MRE represents another potential growth area for the SaMD business as this service may also be offered to other clinical trial customers going forward.

Development of the Company's new 'Non-Invasive MRI Liver Fibrosis' SaMD product continues to progress through its Extended-Proof-of-Concept Trial (**EPOC**).

In addition, several new efficiency enhancement tools were deployed for testing in the Company's service centre that are expected to deliver substantial increases in the service centre's report generation capacity and capability. These tools, which have produced impressive results in testing and validation, enhance process automation utilising artificial intelligence (**AI**).

## Financial & Operating Performance

Continued strong demand in diagnostics, clinical trials, and milestone clinical trial service delivery payments earned in the Company's CRO Services business, contributed to record receipts of \$5M for the quarter, an increase of 57% compared to the September quarter and an increase of 134% over the December 2023 receipts of \$2.1M.

LTM receipts of \$13.1M represents a step-change in the Company's cashflow profile and is more than the total receipts received by the Company during the three financial years from FY2021 to FY2023 combined.

The Company's balance sheet remains strong with a cash balance of \$3.5M at the end of quarter. The Company has a \$3.2M senior debt facility with NAB that was established to partially finance the TrialsWest acquisition (see ASX release dated 2 April 2024) (**NAB Facility**). On 30 September 2024 there was \$3.0M outstanding under the NAB Facility.

After the end of the quarter the Company received a research and development tax incentive refund of \$473,286 (see ASX release dated 24 January 2025).

With respect to item 6 of the Appendix 4C cash flow report for the quarter, payments to related parties of approximately \$100K were made during the quarter. This comprised of \$39K paid to Mr Mitchell Wells for

consulting and Company secretarial services provided during the quarter. The balance was remuneration paid to non-executive directors for their services.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

For further information please contact:

**Andrew Harrison – Chief Executive Officer**

E: [andrewh@resonancehealth.com](mailto:andrewh@resonancehealth.com)

P: +61 (0)8 9286 5300

### About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2\***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2\*. CardiacT2\* is TGA and CE Marking regulatory cleared.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

The Company also operates Clinical Trial Management (CRO Services) and Clinical Trial Site (TrialsWest) businesses that cater to global clinical trial customers.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at [www.resonancehealth.com](http://www.resonancehealth.com) and to follow Resonance Health on LinkedIn.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Resonance Health Limited

**ABN**

96 006 762 492

**Quarter ended ("current quarter")**

31 December 2024

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	5,009	8,197
1.2 Payments for		
(a) research and development	(269)	(523)
(b) product manufacturing and operating costs		
(c) advertising and marketing	(267)	(459)
(d) leased assets		
(e) staff costs	(1,492)	(2,699)
(f) administration and corporate costs	(1,900)	(3,575)
1.3 Dividends received (see note 3)		
1.4 Interest received	6	34
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid	(7)	(7)
1.7 Government grants and tax incentives	-	26
1.8 Other (provide details if material)		
<b>1.9 Net cash from / (used in) operating activities</b>	<b>1,080</b>	<b>994</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses	(3,217)	(3,915)
(c) property, plant and equipment	(14)	(106)
(d) investments		
(e) intellectual property	(42)	(83)
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(3,273)</b>	<b>(4,104)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings	(80)	(160)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other:		
	- Lease payments	(67)	(124)
	- Net payments for cash backed guarantees	-	(12)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(147)</b>	<b>(296)</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	5,776	6,854
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,080	994

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3,272)	(4,104)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(146)	(296)
4.5	Effect of movement in exchange rates on cash held	74	66
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>3,512</b>	<b>3,514</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	3,498	5,760
5.2	Call deposits	16	16
5.3	Bank overdrafts		
5.4	Other (provide details)		
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,512</b>	<b>5,776</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	100
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

7. <b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1 Loan facilities	3,013	3,013
7.2 Credit standby arrangements		
7.3 Other (please specify)		
7.4 <b>Total financing facilities</b>	3,013	3,013
7.5 <b>Unused financing facilities available at quarter end</b>		NIL
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	<p>Secured Financing Facility from National Australia Bank, facility expiry date is 31 March 2027. Interest rate is BBSY + 2.5% per annum.</p>	

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	1,080
8.2 Cash and cash equivalents at quarter end (item 4.6)	3,512
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	3,512
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 28 January 2025

Authorised by: By the Board of Directors of Resonance Health Limited

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.